Cantor Fitzgerald analyst Sarah James initiated coverage of Elevance Health with an Overweight rating and $547 price target. The analyst has concerns about spread compression for the commercial risk market through 2025, but sees Elevance’s actions on repricing as "giving it some cushion." The firm has high conviction in its subsidiary, CarelonRx, achieving its organic growth guidance and also sees earnings upside potential from the recapture of Medicaid redeterminations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELV:
- Elevance Health price target raised to $575 from $571 at Deutsche Bank
- Elevance Health price target lowered to $564 from $577 at TD Cowen
- Elevance Health reports Medical enrollment of 48.1M members on March 31
- Elevance Health raises FY23 adjusted EPS view to greater than $32.70 per share
- Elevance Health reports Q1 adjusted EPS 9.46, consensus $9.26